Is RHYTHM PHARMACEUTICALS, INC. (RYTM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 6.1% / 30% | 0.4% / 30% | 8.06% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 6.1% / 33% | 0.4% / 33% | 8.06% / 5% | ✗ NOT HALAL |
| MSCI | 0.8% / 33% | 81.0% / 33% | 5.4% / 33% | 8.06% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 6.1% / 33% | 0.4% / 33% | 8.06% / 5% | ✗ NOT HALAL |
| FTSE | 0.8% / 33% | 81.0% / 33% | 5.4% / 50% | 8.06% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 89.7% | |
| Operating Margin | -82.2% | |
| Net Margin | -103.6% | |
| Return on Equity (ROE) | -90.5% | |
| Return on Assets (ROA) | -27.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$116M |
| Free Cash Flow | -$117M |
| Total Debt | $4M |
| Debt-to-Equity | 41.5 |
| Current Ratio | 4.4 |
| Total Assets | $480M |
Price & Trading
| Last Close | $81.90 |
| 50-Day MA | $96.71 |
| 200-Day MA | $96.56 |
| Avg Volume | 760K |
| Beta | 2.1 |
|
52-Week Range
$45.91
| |
About RHYTHM PHARMACEUTICALS, INC. (RYTM)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RHYTHM PHARMACEUTICALS, INC. (RYTM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RHYTHM PHARMACEUTICALS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RHYTHM PHARMACEUTICALS, INC.'s debt ratio?
RHYTHM PHARMACEUTICALS, INC.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
What are RHYTHM PHARMACEUTICALS, INC.'s key financial metrics?
RHYTHM PHARMACEUTICALS, INC. has a market capitalization of $5.2B, and revenue of $190M. The company maintains a gross margin of 89.7% and a net margin of -103.6%. Return on equity stands at -90.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.